<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<META HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=iso-8859-1">
<META NAME="Generator" CONTENT="MS Exchange Server version 6.5.7653.12">
<TITLE>Position for Bioinformatics Scientist at Tibotec Virco</TITLE>
</HEAD>
<BODY>
<!-- Converted from text/rtf format -->
<P><FONT SIZE=2 FACE="Arial">Scientist Bioinformatics</FONT>
</P>
<P><FONT SIZE=2 FACE="Arial">Based at: Tibotec Virco BVBA, Mechelen, Belgium</FONT>
<BR><FONT SIZE=2 FACE="Arial">Department: TV-RED Scientific Operations / Computational Virology and Chem/Bio-Informatics</FONT>
</P>
<P><FONT SIZE=2 FACE="Arial">Vacancy Description </FONT>
<BR><FONT SIZE=2 FACE="Arial">In this function you will apply computational techniques to study the effect of mutations in HIV and Hepatitis C genes on the efficacy of antiviral drugs. You will develop new models to predict clinical outcome results of antiviral drugs. You will apply data mining approaches to one of the world’s largest HIV genotype databases to answer scientific questions from internal and external diagnostic experts. In addition, you will be part of projects in drug discovery and development. As a member of the Computational Virology and Chem/Bio-Informatics group you will also play an active role in the development and implementation of the strategy of the group.</FONT></P>
<P><FONT SIZE=2 FACE="Arial"> </FONT>
<BR><FONT SIZE=2 FACE="Arial">Qualifications and Requirements </FONT>
<BR><FONT SIZE=2 FACE="Arial">· Ph.D. (or Masters) degree in Bioinformatics or related field</FONT>
<BR><FONT SIZE=2 FACE="Arial">· Experience with a wide range of bioinformatics and statistical techniques, including sequence analysis, predictive model generation, data mining</FONT></P>
<P><FONT SIZE=2 FACE="Arial">· Expertise in the field of virology highly desirable</FONT>
<BR><FONT SIZE=2 FACE="Arial">· Expertise in scientific programming and/or scripting.</FONT>
<BR><FONT SIZE=2 FACE="Arial">· Outstanding communication and team work skills.</FONT>
</P>
<P><FONT SIZE=2 FACE="Arial">Contact Herman van Vlijmen (hvvlijme at tibbe.jnj.com) </FONT>
</P>
<P><FONT SIZE=2 FACE="Arial">Tibotec (<A HREF="http://www.tibotec.com">http://www.tibotec.com</A>) is a pharmaceutical research and development </FONT>
<BR><FONT SIZE=2 FACE="Arial">company with headquarters in Belgium and operating subsidiaries in the </FONT>
<BR><FONT SIZE=2 FACE="Arial">United States and Ireland. The company is a subsidiary of Johnson & </FONT>
<BR><FONT SIZE=2 FACE="Arial">Johnson. Tibotec is dedicated to the discovery and development of novel </FONT>
<BR><FONT SIZE=2 FACE="Arial">drugs for HIV/AIDS and other infectious diseases with the ultimate aim </FONT>
<BR><FONT SIZE=2 FACE="Arial">of enhancing and extending peoples lives.</FONT>
</P>
<P><FONT SIZE=2 FACE="Arial">Virco (<A HREF="http://www.vircolab.com">http://www.vircolab.com</A>) is a research-driven biotech company with headquarters in Belgium (Virco BVBA) and U.S. offices in New Jersey and North Carolina (Virco Lab, Inc.), and a subsidiary of Johnson & Johnson. Virco is a pioneer in the field of HIV-1 drug resistance testing. Virco's product portfolio currently includes the Antivirogram, an HIV-1 phenotyping assay, and vircoTYPE HIV-1 . vircoTYPE HIV-1 is a unique and proprietary approach to predict the virus' susceptibility to antiretroviral drugs from the genotype and uses the world's largest HIV-1 resistance database. </FONT></P>
<BR>
<BR>
</BODY>
</HTML>